Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Involves transaction of at least 0.5% of the listed shares of a company. Sanofi Consumer Healthcare India Ltd share price was up by 4.03% from the previous closing price of ₹5,142.70.

(Reuters) -Sanofi and partner AstraZeneca have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

The newly merged company also formed a subsidiary known as Sanofi Pasteur, which is today one of the world’s largest producers of vaccinations for a variety of conditions, including tetanus ...

SBI Magnum Midcap Fund - Direct (G) 217.19 3,18,972 1.01 SBI Magnum Midcap Fund - Direct (IDCW) 217.19 3,18,972 1.01 Aditya Birla SL Frontline Equity Fund (G) 167.89 2,46,566 0.55 Aditya Birla SL ...